72 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이창범-
dc.date.accessioned2018-05-02T05:05:26Z-
dc.date.available2018-05-02T05:05:26Z-
dc.date.issued2014-03-
dc.identifier.citationPlos One, 2014, 9(3), e87799en_US
dc.identifier.issn1932-6203-
dc.identifier.urihttp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087799-
dc.identifier.urihttp://repository.hanyang.ac.kr/handle/20.500.11754/71201-
dc.description.abstractAims:To compare the commonly prescribed oral anti-diabetic drug (OAD) combinations to use as an add-on therapy with insulin glargine in patients with uncontrolled type 2 diabetes despite submaximal doses of OADs.Methods:People with inadequately controlled type 2 diabetes (n = 99) were randomly assigned on a 1:1:1 basis to receive insulin glargin, with fixed doses of glimepiride, metformin, and glimepiride plus metformin. Outcomes assessed included HbA1c, the changes in fasting glucose levels, body weight, serum lipids values, insulin dose and symptomatic hypoglycemia.Results:After 24 weeks, HbA1C levels improved from (mean +/- SD) 8.5 +/- 0.9% to 7.7 +/- 0.8% (69.0 +/- 10.0 mmol/mol to 60.8 +/- 8.6 mmol/mol) with insulin glargine plus metformin, from 8.4 +/- 1.0% to 7.7 +/- 1.3% (68.8 +/- 10.6 mmol/mol to 61.1 +/- 14.4 mmol/mol) with insulin glargine plus glimepiride and from 8.7 +/- 0.9% to 7.3 +/- 0.6% (71.7 +/- 9.8 mmol/mol to 56.2 +/- 6.7 mmol/mol) with insulin glargine plus glimepirde plus metformin. The decrease in HbA1c was more pronounced with insulin glargine plus glimepiride plus metformin than with insulin glargine plus metformin (0.49% [CI, 0.16% to 0.82%]; P = 0.005) (5.10 mmol/mol [CI, 1.64 to 8.61]; P = 0.005) and insulin glargine plus glimepiride (0.59% [CI, 0.13% to 1.05%]; P = 0.012) (5.87 mmol/mol [CI, 1.10 to 10.64]; P = 0.012) (overall P = 0.02). Weight gain and the risk of hypoglycemia of any type did not significantly differ among the treatment groups.Conclusion:The combination therapy of metformin and glimepiride plus glargine insulin resulted in a significant improvement in overall glycemic control as compared with the other combinations.en_US
dc.description.sponsorshipThis study was funded by Sanofi-Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.en_US
dc.language.isoenen_US
dc.publisherPublic Library Scienceen_US
dc.subjectINDIVIDUALIZING GLYCEMIC TARGETSen_US
dc.subjectORAL-THERAPYen_US
dc.subjectCONTROLLED-TRIALen_US
dc.subjectPLUS METFORMINen_US
dc.subjectMELLITUSen_US
dc.subjectROSIGLITAZONEen_US
dc.subjectSULFONYLUREAen_US
dc.subjectMANAGEMENTen_US
dc.subjectREGIMENSen_US
dc.subjectFAILUREen_US
dc.titleComparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetesen_US
dc.typeArticleen_US
dc.relation.no3-
dc.relation.volume9-
dc.identifier.doi10.1371/journal.pone.0087799-
dc.relation.page0-0-
dc.relation.journalPLOS ONE-
dc.contributor.googleauthorPark, Cheol-Young-
dc.contributor.googleauthorKang, Jun Goo-
dc.contributor.googleauthorChon, Suk-
dc.contributor.googleauthorNoh, Junghyun-
dc.contributor.googleauthorOh, Seung Joon-
dc.contributor.googleauthorLee, Chang Beom-
dc.contributor.googleauthorPark, Sung Woo-
dc.contributor.googleauthor이창범-
dc.relation.code2014037807-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidlekang-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE